

Product datasheet

AAV2 VP3, recombinant protein

Short overview

 Cat. No.
 640825

 Quantity
 10 μg

Concentration 100 µg/ml (1.61 µM)

Product description

Formulation Liquid, 6 M urea in PBS

Source Escherichia coli

Molecular Weight 62.2 kDa (calculated Mw from aa sequence)

Purity > 90% (determined by SDS PAGE)

Product description N-terminal His-tagged (MGSSHHHHHHHSSGLVPRGSH) recombinant AAV2 capsid protein VP3

Purification Ni-NTA chromatography

Storage -80°C

Intended use Research use only

Application Capillary electrophoresis (CE), Dot blot, SDS PAGE, WB

Applications

Capillary electrophoresis (CE) Assay dependent

Dot Blot 100 ng, depending on primary antibody and detection method


SDS PAGE 1 µ

Western Blot (WB) 5-20 ng, depending on primary antibody and detection method

Background

The AAV capsid consists of three capsid proteins, i.e. VP1, VP2 and VP3, which differ in their N-terminus and encapsulate the genomic ssDNA. In native virus particles, the three proteins form subunits with a ratio of 1:1:10 (VP1:VP2:VP3), in a total number of 60 subunits per capsid. The recombinant AAV2 VP3 protein in combination with recombinant AAV2 VP1 (Cat. No. 640823) and recombinant AAV2 VP2 (Cat. No. 640824) can be used to create a mixture with the precise molar ratio of 1:1:10 to compare the protein composition of the viral capsid in your sample by protein detection methods, e.g. western blot. All three recombinant AAV2 capsid proteins are available as set (Cat. No. 72001) or as individual proteins (Cat. No. 640823, 640824, 640825). Note: please find an example how to prepare western blot samples in the pipetting scheme below. Aliquots of the remaining samples can be stored at -80°C for reuse.

Product images



Western blot analysis of recombinant AAV2 VP3 (Cat. No. 640825) with B1 antibody. Western blot analysis was performed on different amounts of recombinant AAV-VP3 ranging from 25 ng to 100 ng. The PVDF membrane was blocked with 5% dry milk in PBST (PBS + 0.1% Tween 20) for 1 h at RT. The primary antibody anti-AAV VP1/VP2/VP3 mouse monoclonal, B1 (Cat. No. 690058) was diluted in blocking buffer (antibody concentration 0.5 μ g/ml) and incubated for 1 h at RT. The secondary antibody goat anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 0.2 μ g/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using PierceTM ECL Western Blotting Substrate.



15-

Pipetting scheme for western blot analysis using a mix of the AAV2 capsid proteins (Cat. No. 640823, 640824, 640825). To create a VP mixture with the molar ratio 1:1:10 (VP1:VP2:VP3), please pre-dilute VP1 and VP2 1:10 to yield a final concentration of 10 μ g/ml (green table). Pipette the pre-diluted VP1 and VP2 proteins and mix them with the undiluted VP3 protein in your sample buffer and water (blue table). The example with 2x and 3x sample buffer and the required volumes are indicated in the pipetting scheme. Thus, in one lane, 10 μ l of the VP mix can be loaded onto the SDS PAGE and analyzed by Western blot using the B1 antibody (Cat. No. 690058, Cat. No. 61058-488, Cat. No. 61058-647).Undiluted = 100 μ g/ml, pre-diluted = 10 μ g/ml



AAV2 VP3, recombinant protein